Glioblastoma Prognosis – New Hope With DCA Treatment

New information just released about glioblastoma prognosis & new treatment option.

You can buy DCA at

Watch The News Release Video Below!

Doctors say,  ”Glioblastoma Prognosis is not good”. Wikipedia says, “Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor in humans… most prevalent form of primary brain tumor, occuring in only 2–3 cases per 100,000 people in Europe and North America.

Glioblastoma Prognosis

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, and surgery. Glioblastoma prognosis is very poor, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible. This can be followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic care with corticosteroids.

glioblastoma prognosis

Other than the brainstem gliomas, it has the worst prognosis of any CNS malignancy.”  Glioblastoma prognosis is usually given in months – not years.  Here is a short list of brain cancer symptoms.

The information states that glioblastoma prognosis using conventional treatments is poor but it does not say anything about glioblastoma prognosis using DCA. DCA is also known as sodium dichloroacetate, NaDCA, and dichloroacetate. This is not a drug – so no doctors or pharmacists will prescribe it – it is a simple, unpatentable molecule.

Representatives from the University of Alberta (UA) in Canada claimed 2007 that it is possible to use DCA as a cure for various forms of cancer. One of the professors from the abovementioned University PROVED that DCA helps with regression of lung and breast cancers, as well as brain tumors (among others).

The results of the study may be viewed in the research journal Cancer Cell published by the researchers from UA (including cardiologist, Dr. Evangelos Michelakis, and Dr. Sebastien Bonnet).   This research can drastically improve glioblastoma prognosis and the severity of its symptoms.

Because DCA is a simple, small molecule it is able to cross the blood-brain barrier when many other treatments have a molecular size too large to pass through – this alone improves the glioblastoma prognosis.

Otto Warburg, a German biochemist, won a Nobel Prize for discovering, in 1930, that tumor cells were a product of metabolic disorder. The mitochondria begin using decomposed glucose for energy rather than oxygen.

Dr. Michelakis, the Canadian Researcher, took this 80 year old finding and attempted to restore the functioning of the mitochondria to the affected cells. He used dichloroacetate (DCA) on cancer cells in rats and discovered that the restoration of the damaged mitochondria,  caused the tumor mass to shrink  by 70%  in just three weeks. Unlike other cancer therapies,  the DCA therapy only worked on the cancer cells and let the healthy cells unchanged.

50 volunteers with glioblastoma multiforme and wanting to improve their glioblastoma prognosis  participated in the University trials. In March 2008 an article was published in a reputable periodical “Nature”, indicating that DCA works on the same biochemical trials as pyruvate kinase, which is responsible for control over means of conversion of glucose oxygen or oxygen free. According to commentators, DCA seems to switch back the cellular biochemical trails to oxygen breathing.

For more information on DCA and improving Glioblastoma Prognosis visit where the latest news videos are posted.